The “reset button” revisited: why high activity 131I therapy of advanced differentiated thyroid cancer after dosimetry is advantageous for patients
Sign Up to like & getrecommendations! Published in 2017 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-017-3649-9
Abstract: The treatment of advanced differentiated thyroid cancer (DTC) remains challenging. In spite of our best efforts, about 15% of patients with high-risk DTC have a significantly reduced life expectancy as many do not respond sufficiently… read more here.
Keywords: medicine; strategy; advanced differentiated; absorbed dose ... See more keywords
A prospective observational multicentric pan India study of lenvatinib in radio-iodine refractory advanced differentiated thyroid cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e18106
Abstract: e18106Background: Management of advanced differentiated thyroid cancer refractory to radio-iodine (RAI) has taken a new turn with the results of SELECT trial. Physicians are learning to use lenvati... read more here.
Keywords: advanced differentiated; differentiated thyroid; radio iodine; thyroid cancer ... See more keywords
Prognostic factors in patients with advanced differentiated thyroid cancer treated with multikinase inhibitors - a single Brazilian center experience.
Sign Up to like & getrecommendations! Published in 2021 at "Archives of endocrinology and metabolism"
DOI: 10.20945/2359-3997000000364
Abstract: Objective The aim of this study was to describe the real-world experience multikinase inhibitors (MKI) in the treatment advanced differentiated thyroid carcinoma (DTC) refractory to radioactive iodine (RAIR) therapy. Methods We reviewed the records of… read more here.
Keywords: advanced differentiated; prognostic factors; multikinase inhibitors; differentiated thyroid ... See more keywords